Pharsight Expands Global Presence Through InforSense Chinese Distributor, Companies to Collaborate On Use of Biomarkers in PK/PD Modeling

MOUNTAIN VIEW, Calif., and LONDON, Oct 7, 2008 — Pharsight Corporation, a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, and InforSense Ltd., the leading provider of next-generation business and scientific intelligence tools, today announced that they have signed an agreement for InforSense to distribute Pharsight products in China through its Shanghai based subsidiary. This relationship marks Pharsight’s entry into the growing Chinese life sciences marketplace.

As part of the agreement, InforSense will represent Pharsight’s market-leading software for pharmacokinetic and pharmacodynamic (PK/PD) analysis, reporting, archiving, and data visualization. InforSense will provide distribution services for Pharsight within the Chinese pharmaceutical and biotech research and development market, including sales and marketing, end-user training, and maintenance and support services.

Pharsight and InforSense have also initiated a strategic partnership to deliver translational research solutions to the pharmaceutical industry. The strategic partnership includes opportunities for product-based collaborations to utilize biomarkers in clinical PK/PD modeling.

“This agreement strengthens Pharsight’s ability to take advantage of the exceptional growth opportunities in China as research and development activities expand,” said Daniel L. Weiner, Ph.D., senior vice president and chief technology officer at Pharsight. “There is a strong demand in our customer base for more dynamic analysis and visualization of PK/PD data and the integration of genotypic and other biomarker data. Partnering with InforSense will enable Pharsight to take advantage of their flexible, high-throughput analytics technology and expertise with molecular data to enable more effective PK/PD modeling. We look forward to a successful distribution alliance and fruitful collaboration, based on the respective strengths of each company’s tools and technologies.”

“Pharsight’s tools are a fundamental requirement in PK/PD, particularly in the pharmaceutical industry, and we are pleased to be working with them in this area,” said Jonathan Sheldon, Ph.D., chief scientific officer at InforSense. “Bringing together our capabilities in genotypic and other molecular analysis with Pharsight’s PK/PD tools and expertise is a major step towards making the goal of translational research a reality.”

To initiate the partnership, Pharsight will participate at several events sponsored by InforSense in Shanghai, China on November 3-5, 2008, as part of the First International Meeting on Drug Discovery Pipeline and Informatics Solutions. On November 3, Daniel L. Weiner, Ph.D., Pharsight senior vice president and chief technology officer, will speak to conference attendees on the strategic value of modeling and simulation for improving the efficiency of clinical drug development. On November 4-5, Dr. Weiner will lead an applied training workshop on PK/PD data analysis and modeling methods, utilizing Pharsight’s WinNonlin(r) software.

More information about this event is available at www.drugdiscovery-china.cn.